LYRA THERAPEUTICS INC

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

07 5月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

06 5月 2025 16:01:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

13 3月 2025 16:01:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 11月 2024 16:01:58 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

15 10月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

27 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

14 8月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

21 5月 2024 09:14:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

06 5月 2024 07:59:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

30 4月 2024 16:04:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

26 4月 2024 16:51:11 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

21 3月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 3月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 11月 2023 16:01:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics to Participate in Upcoming Investor Conferences

07 11月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer

16 10月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

12 9月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics to Participate in Upcoming Investor Conferences

06 9月 2023 15:00:28 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

29 8月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

08 8月 2023 16:01:00 条件 Nasdaq GlobeNewswire